Androgen insufficiency is a recognized cause of sexual dysfunction in men and women. Age-related decrements in adrenal and gonadal androgen levels also occur naturally in both sexes. At present, it is unclear if a woman's low serum androgen level is a reflection of the expected normal age-related decline or indicative of an underlying androgen-deficient state. We studied premenopausal women with no complaints of sexual dysfunction to help define a normal female androgen profile. In all, 60 healthy, normally menstruating women, ages 20-49 y, were studied. The Abbreviated Sexual Function Questionnaire was administered along with a detailed interview. Radioimmunoassay measurements of morning serum testosterone (T), free testosterone (fT), dehydroepiandrosteronesulfate (DHEAS), sex hormone-binding globulin (SHBG), and free androgen index (FAI) were measured during days 8-15 of the menstrual cycle. In women 20-49 y old without complaints of sexual dysfunction, serum androgen levels exhibit a progressive stepwise decline. Comparing values obtained in women age 20-29 y to those obtained in women 40-49 y, specific hormone decrements were DHEAS 195.6-140.4 lg/dl, serum T 51.5-33.7 ng/dl, fT 1.51-1.03 pg/ml. SHBG did not change significantly in women in this age group. The FAI reflected the age-related decrease in female androgen levels. The framework for the development of a female androgen profile in women with no complaints of sexual dysfunction has been established, and an age-related decrease in testosterone and its adrenal precursor, DHEAS, has been demonstrated. The FAI mirrors these decreases and its usefulness in clinical practice is confirmed. A precipitous decline in all androgens occurs after the decade of the 20s, yet SHBG does not show a significant change throughout the premenopausal years.
Introduction
The importance of male hormones (androgens) in female health is often only apparent when a woman's androgen levels are present in excess. Androgen hypersecretion, whether from an ovarian or adrenal source, causes virilism and hirsutism, symptoms demanding prompt medical attention.
Inadequate androgen levels adversely impact women's health, and female androgen insufficiency syndrome has recently been proposed. 1 Progress in this field has been hampered by the lack of precise analytical methods and the lack of experimental models. This is further confounded by psychosocial and relationship issues as well as the changing hormonal status of women as they age. Testosterone insufficiency also shares symptoms with a variety of medical and psychological conditions, such as depression and chronic illness.
An age-related decrease in androgen levels, including gonadal testosterone and the adrenal androgen dehydroepiandrosterone-sulfate (DHEAS), has been confirmed by many investigators, in order to differentiate women with normal age-related decrements in androgen levels from those who are experiencing a bona fide age-defined androgen deficiency. [2] [3] [4] [5] [6] [7] Plasma androgen levels in control populations, in the presence or absence of normal sexual function, have not been addressed. This is quite important, as suggested in Laumann's study. 8 His group found that 43% of women (n ¼ 1749) between the ages of 18 and 59 y had some form of sexual dysfunction. A more careful dissection of these data will show that between 30 and 32% of women suffered from decreased sexual desire, and that this number varied little across age, expressed in decades. Since testosterone insufficiency is one of the several causes of decreased libido, the relationship of androgen blood test values in aging women without sexual dysfunction must be better defined.
Sexual problems surface in both sexes coincident with the age-related decline in gonadal and adrenal androgen levels. However, the relationship between low androgen levels and female sexual dysfunction remains unclear. The aim of this study was to determine testosterone (T) and free testosterone (fT) levels in healthy premenopausal women between the ages of 20 and 49 y with no complaints of sexual dysfunction. To this end, we screened healthy premenopausal women for sexual dysfunction using selected domains of the Sexual Function Questionnaire (SFQ) and evaluated androgen levels only in women who were proven not to have complaints of sexual dysfunction.
Materials and methods

Participants
In all, 90 healthy, premenopausal volunteers, between the ages of 20 and 49 y, presented for evaluation to be normal controls. Interested women responded to posters placed at the entrance to the above medical institutions in a manner acceptable to the respective Institutional Review Boards. These included women having routine examinations, family members, and interested medical personnel. The inclusion criteria required that subjects were in stable, heterosexual relationships and were free of acute or chronic medical and/or psychological illnesses. Women were screened by structured clinical interviews for complaints of women's sexual problems: irregular menstrual cycles, chronic disease, substance abuse, anxiety, depression, and medication use (especially oral contraceptives). The absence of women's sexual concerns was defined through subjective reports of libido, arousal, and orgasm during an interview, as well as through responses to a clinical survey instrument (Abbreviated Sexual Function Questionnaire, ASFQ).
In all, 10 women in the initial sample failed to complete the survey and were therefore excluded. Of the remaining 80 participants, an additional 12 were screen failures, reducing the sample further to 68 females. Eight were dismissed due to questions on blood sampling, collection, and storage. The final sample for study consisted of 60 women without evidence of sexual dysfunction and with complete laboratory information.
Laboratory testing
Blood samples for hormone analysis were drawn in the morning between 0800 and 1200. Although the existence of a circadian rhythm for testosterone in women, as is known for men, has been debated, the evidence now points to higher levels in the forenoon. 9, 10 Blood samples were also collected during the middle third of the menstrual cycle, between days 8 and 15, when androstenedione and testosterone levels are the highest. 11, 12 The blood samples were quickly centrifuged, and stored frozen at À201 C.
Hormone analyses
Serum samples were coded and maintained frozen at -201C. To avoid intra-assay variability, each hormone was measured in a single continuous hormone assay. Hormone analyses were performed using commercially available radioimmunoassay kits.
DHEAS was measured using a kit from by Diagnostic Products Corporation of Los Angeles, California, USA. Crossreactivity was 100% for DHEAS and 0.121% with androstenedione, 15% with 9-hydroxyandrostenedione, 0.046% with estrone 3 sulfate, 0.55% with androsterone sulfate, 0.5% with DHEA and negligible for all other steroids tested. The interassay coefficient was 6.3-7.7%.
FT was measured using the Coat a Count Kits of Diagnostic Products Corporation, Los Angeles, California, USA. Crossreactivity was 0.41% for dihydrotestosterone, 0.01% for androstenedione, 0.10% for methyl testosterone and o0.01% for all other steroids tested. The interassay coefficient was 8.0-8.5%.
The total serum testosterone levels were measured with the Immunochem serum testosterone kit of ICN Biomedicals Inc., Diagnostic Division of Costa Mesa, California, USA. The crossreactivities of the antiserum used in the T RIA were 7.8% for dihydrotestosterone, 2.0% for 11-oxosterone, 2.20% for 5 alpha androsterone 3 beta, 17 beta diol, and less than 0.01% for all other steroids tested. The interassay coefficients were 9.57-10%.
SHBG measurements were performed using the double antibody method of Diagnostic Services Lab of Webster, Texas, USA. Crossreactivity was 100% for SHBG and negative for TBG, IgG, albumin, and all other proteins tested. The assays for serum pregnenolone and 17-hydroxypregnenolone were performed by Quest Laboratory in Tarzana, California, USA.
Free Androgen Index (FAI) 1, 13 The calculation of the FAI was carried out using the following formula:
Total testosterone ng=dl Â 0:0347
As some women may be unaware of what constitutes 'normal' sexual functioning, or may seek to provide socially appropriate answers during clinical interview, the ASFQ was used to provide a more objective measure of FSD. The SFQ comprises 34 questions that assess desire, lubrication, pain/ discomfort with intercourse, emotional stress, pleasure, satisfaction, and ability to achieve orgasm. 14 Respondents were asked to indicate the frequency of sexual activity over the past 4 weeks using a sevenpoint ordinal response scale in which '0' indicated no activity and '6' indicated very frequent activity (416 sexual encounters during the past month). Respondents were also asked to indicate how frequently they experienced genital warmth and sensation, as well as intimacy and enjoyment, anxiety, orgasm, and vaginal lubrication or tingling. For these questions, a '0' indicated that the respondent had not been sexually active, whereas a '5' indicated a very frequent, intense, or pleasurable occurrence of the event. Finally, for questions about desire, anxiety, perceived importance of sexual behavior, and initiation of sexual activity, a five-point ordinal scale was used. A '1' indicated no desire, worry, concern, or initiation, and a '5' indicated very frequent desire, worry, concern, or initiation.
Factor analysis of the original instrument revealed seven domains: Desire, physical Arousal-sensation, physical Arousal-lubrication, Enjoyment, Orgasm, Pain, and Partner Relationship, which demonstrated moderate to high internal consistency (ranging from 0.65 to 0.91).
Questions concerning fear of pain, perceived emotional intimacy and relationship-centered anxiety, which constitute the domains of Enjoyment, Pain, and Partner, were eliminated from screening questionnaires to maintain a focus on the physiological sexual response in this study. The remaining domains of Desire, Arousal-lubrication, Arousalsensation, and Orgasm were called the Abbreviated Sexual Function Questionnaire (ASFQ). These 15 questions, along with response options and scoring, are highlighted in Appendices A and B respectively. The criteria for determining normal function based on the sum of questions comprising each domain are provided in Appendix B. The validation of this four domain, 15-item version of the SFQ is discussed in Results section below.
Statistical analyses
Cronbach's alpha and Gutman split-half reliabilities were calculated to determine the internal consistency of the abbreviated SFQ. Principal components analysis with varimax rotation was used to determine the survey's factor structure and ultimately, the number of domains that comprised selected survey items.
Individual patient responses were scored and summed for each unobserved factor (or domain), thereby creating scores for multiple dimensions of sexual function. Descriptive statistics (ie means and standard errors) were calculated for the entire population. The mean survey responses were then compared against the criteria for defining normal function per domain, based on guidelines provided in the original instrument.
14 Lab data for the 60 women were also separated into three age groups: women aged 20-29 y, women aged 30-39 y, and women aged 40-49 y. Means and standard errors were computed for hormonal assays collected in each subgroup (ie DHEAS, SHBG, T, fT, and the FAI). The small sample size of each of the three groups precluded the creation of Gaussian curves by decade, as the limited number of women in each resulted in large standard deviations. Thus, standard error of the mean was used to create lab ranges for each cohort instead.
Multiple range (Bonferroni) t-tests were conducted to determine significant differences in the mean hormone values among the three cohorts. In addition, Pearson's product moment correlations were used to assess bivariate, linear associations between increasing age (in years) and hormone levels for all participants. Finally, the relationship between age, adrenal, and C-19 steroids (DHEAS and total testosterone) was compared to that reported previously in the clinical literature. As these few studies were composed of very heterogeneous populations, we could not perform meta-analysis of the associations between age and hormones. Confidence intervals (95%) were used to evaluate all pairwise comparisons of means. All P-levels reported are two-tailed. Analyses for this study were conducted using SPSS Statistical Software for Windows, Version 10.0 (Chicago, Illinois, USA, 2002).
Results
Patient population
A total of 60 women meeting the inclusion criteria were selected. The mean age of the 60 patients was 35.0 y (77.3; range: 22-48 y).
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Instrument validation
Reliability analysis of the 15 SFQ questions revealed a strong internal consistency, with a Cronbach's alpha coefficient of 0.96 and Gutman's split-half reliabilities of 0.89 and 0.98, respectively. Interitem correlations also ranged from moderate to high (0.47-0.87), consistent with the analysis of the original instrument. 14 The results of the principal components analysis confirmed the four domains of sexual function generated in the original analysis; these are depicted in Figure 1 . Domain 1, the latent variable termed 'Desire', comprised the following questions: (1) over the last 4 weeks, how often have you had pleasurable thoughts and feelings about sexual activity? (2) over the last 4 weeks, how often have you wanted to be sensually touched and caressed by your partner?; (3) over the last 4 weeks, how often have you wanted to take part in sexual activity?; (4) over the last 4 weeks, how often have you initiated sexual activity with your partner?; (15) over the last 4 weeks, how often did you take part in sexual activity with penetration (e.g. vaginal penetration and intercourse)?; and (28) thinking about your sexual life over the last 4 weeks, how often did you look forward to sexual activity? Domain 2, referred to as 'Arousal-sensation', comprised the following questions pertaining to genital stimulation: (7) over the last 4 weeks, how often did you have a feeling of warmth in your vagina/genital area when you took part in sexual activity?; (8) over the last 4 weeks, in general, how much warmth did you feel in your vagina/genital area when you took part in sexual activity; (9) over the last 4 weeks, how often did you have a sensation of pulsating (tingling) in your vagina/genital area when you took part in sexual activity? and (10) over the last 4 weeks, in general, how much pulsating (tingling) in your vagina/genital area did you notice when you took part in sexual activity?
The third domain, entitled 'Arousal-lubrication', consisted of questions concerning vaginal wetness, specifically: (11) over the last 4 weeks, how often did you notice vaginal wetness/lubrication when you took part in sexual activity? and (12) over the last 4 weeks, in general, how much vaginal wetness/ lubrication did you notice when you took part in sexual activity?
The fourth and final domain of 'Orgasm' asked about the frequency, pleasure, and ease of orgasmic response: (24) over the last 4 weeks, how often did you have an orgasm when you took part in sexual activity (maybe with or without a partner); (25) over the last 4 weeks, in general, how pleasurable were the orgasms that you had? and (26) over the last 4 weeks, in general, how easy was it for you to reach orgasm?
Factor loadings of questions across all four domains were positive and high, ranging from 0.74 to 0.91, with no crossfactor loadings. Figure 2 shows mean responses (7s.e.m.) to each of the four domains of the abbreviated SFQ. Using the criterion from Quirk et al, 14 (Appendix B), we determined that a score greater than 23 was needed to exhibit normal sexual desire. The 60 women surveyed had a mean score of 27.1 for desire. Similarly, a score greater than 14 defined normal arousal sensation, whereas a score of nine or higher determined normal arousal lubrication. Our sample had a mean score of 19.7 for the Arousal-sensation domain, and a mean score of 11.2 on the Arousallubrication domain. Finally, women without sexual dysfunction were required to score 12 or better on the Orgasm domain; the 60 respondents scored an average of 14.9. Having established, that the 60 Figure 1 Rotated factor solution confirming four-factor structure of the 15 items selected from the SFQ. Normal androgen levels in premenopausal women A Guay et al women were free of sexual dysfunction, we proceeded to examine their laboratory data from blood analyses.
Questionnaire response
Hormone levels and age Table 1 shows descriptive statistics for each of the five hormone assays according to age in decades. With respect to adrenal hormones, DHEAS was highest in women aged 20-29 y, at a mean of 195.6 mg/dl. This was significantly higher than the mean DHEAS score for women 30-39 y (154.9 mg/dl; P ¼ 0.001) and for women aged 40-49 y (140.4 mg/dl; Po0.001). Women in their 30s were also slightly but significantly higher on DHEAS than their middle-aged counterparts (P ¼ 0.046).
SHBG values were similar among all three cohorts, showing no significant difference between groups. A mean of 51.1 nmol/l was reported for the 20-29 y cohort, while a mean of 48.5 nmol/l was observed among those aged 30-39 y. In addition, a mean of 52.7 nmol/l was reported for women aged 40 y and older (all P-values40.65). The FAI, however, was almost twice as high for women aged 20-29 y (mean: 4.34), compared to women in their 30s (mean 2.50; Po0.001) or 40s (mean: 2.46; Po0.001). Since SHBG does not change, total testosterone, therefore, reflects that of free testosterone.
The highest mean T level was observed among the youngest women, aged 20-29 (mean ¼ 51.5 ng/dl). This value was significantly higher than the mean value of 33.7 ng/dl observed among women aged 30-39 y (P ¼ 0.001) and the mean value of 32.8 ng/dl observed in women aged 40-49 y (P ¼ 0.03). Between-group differences were less dramatic with respect to the fT. Mean values were highest, again, for the youngest cohort (women 20-29 y: 1.51 pg/ml; women 30-39 y: 1.10 pg/ml (P ¼ 0.04); women aged 40-49 y: 1.02 pg/ml; mean values significantly different between youngest and oldest women where P ¼ 0.04). Table 2 briefly summarizes the bivariate correlations observed between age (in years) and each hormone for the entire sample of 60 women. Only SHBG did not exhibit a significant correlation with age (r ¼ 0.10; P ¼ 0.67). However, significant, moderate, and negative correlations were observed between age and the four remaining hormones. The strongest correlation was between fT and age (r ¼ À0.46; Po0.001), followed by FAI (r ¼ À0.35; P ¼ 0.006) and DHEAS, respectively (r ¼ À0.35; P ¼ 0.009). The weakest significant correlation was observed between T and age in years (r ¼ À0.30; P ¼ 0.02).
Discussion
Our data indicate that serum levels of androgens decrease with age in women as reported for men. It is generally accepted that a decrease in the adrenal androgen precursor, DHEAS, takes place in women, as well as in men, as they age. However, the decrease in testosterone with age is not well documented. Figure 3 provides a comparison of DHEAS levels Normal androgen levels in premenopausal women A Guay et al reported at various ages in the present study and in five previously published works. [2] [3] [4] [5] [6] Our data are consistent with those in the literature concerning the decrease of DHEAS with age in women who were accepted as healthy controls. This is attributed to the fact that assays for DHEAS are fairly similar and easy to perform, so that the results do not vary as much from laboratory to laboratory. Alternatively, DHEAS is not bound to SHBG and therefore not prone to changes when SHBG varies with different clinical conditions, and also that DHEAS does not vary during the menstrual cycle.
Our data on testosterone also show that there is a decrease in this hormone, irrespective of whether it was determined by T, fT, or by calculating the FAI. Figure 4 compares the total testosterone levels by age in the present study of normal women to a similar study of 33 women with normal sexual function by Zumoff. 7 Zumoff and co-workers first reported a linear decline of T with age. The mean T was recorded at approximately 28.0 ng/dl for women in their 20s, 25.0 ng/dl for women in their 30s, and 20.0 ng/dl for women over 30 y old. We report a larger decline in T for women in their 30s, with mean values dropping from approximately 52 ng/dl in the 20-29 y cohort to approximately 34 ng/dl and 33 ng/dl in the 30-39-and 40-49-year-old groups, respectively. The larger sample size and use of a clinical assessment tool to screen women for sexual dysfunction may explain the higher T values observed herein. The possible implication is that we have excluded (by the ASFQuestionnaire) some women who had lower T levels, which may have been manifested by a decrease in sexual desire.
The measurement of fT by the analog method also showed a decrease with age. Again, the largest decrease was observed among young women in their 30s. The range is not as wide using the fT, as with the other androgen measurements, but showed the best correlation with decreasing age. 15 Vermeulen, however, suggests that the results of the analog-free methods correlate highly with the results of the free testosterone by equilibrium dialysis (r ¼ 0.937), an assay considered to be the gold standard, albeit difficult for many laboratories to perform. A major concern is that the analog substance used in the assay is a trade secret and cannot be evaluated properly and independently. Wilke, and others, have suggested that the analog-free testosterone is not affected by the level of SHBG, that is, that there is not a good negative correlation as there should be. 16 He found an r ¼ À0.09, while Winters found a decent relationship with an r ¼ À0.30. 17 We have also shown a good relationship, using larger numbers of samples evaluated, with r ¼ À0.31.
13
A critical finding of our work is the marked decrease in androgens observed among women in their 30s. There is a smaller drop in testosterone levels during the 40s. This observation is consistent with previous reports. 2, 4 Even the decrease in DHEAS is greatest after the 20s, but there is a more consistent decrease that continues in the 30s and 40s.
SHBG was not significantly changed between the ages of 20 and 49 y (ie the premenopausal period). As SHBG is an integral part of the calculation of the FAI, the fact that SHBG does not change with age indicates that the FAI decrease with age is related to a decrease in total, free, or bioavailable testosterone and not due to protein binding. This would lend credence to the recommendation of the Consensus Conference on Female Androgen Deficiency to use the FAI in screening women for testosterone deficiency. 1 Although studies have been conducted during the perimenopausal transition and the Figure 3 Relationship between the decrease in DHEAS and the increase in age: a comparison of our data with the literature (adapted from Labrie et al, 2 Maccario et al, 3 Sulcova et al, 4 Orentreich et al 5 and Lasley et al .
Normal androgen levels in premenopausal women A Guay et al postmenopausal years, to our knowledge, this is the only study to have evaluated SHBG during the younger premenopausal years. Gershagen examined 17 women over a period of 3 years starting 1 1 2 y prior to menopause. There was a slight decrease (7%) just before menopause, with a larger decrease (14%) during the next 18 months. 18 Burger studied 172 women during a 7-y follow-up. He found that the mean SHBG levels decreased by 43% from 4 y before to 2 y after the final menstrual period (FMP). He found the greatest change to be the 2 y before the FMP, with the median age pre-FMP being 51 y and the median age post-FMP being 54 y. 19 Rannevik also showed a clearcut fall in SHBG concentration related to the menopause, 20 while Bancroft showed no significant change in SHBG levels in comparing pre-, peri-, and postmenopausal women. 21 It should be noted that this study may have some empirical limitations. The small sample size does not allow the creation of Gaussian curves for each decade, with ranges expressed as 72 standard deviations of mean androgen values. Therefore, we can only offer a guide to the normal values that may be replicated in larger, carefully screened populations.
Also, the use of the SFQ to screen patients for sexual dysfunction results in a slight inflation of standard errors around mean domain scores. However, as our study is primarily descriptive in nature and does not use predictive modeling, we do not deem this a serious limitation. This notion is further supported by Figures 3 and 4 , which show the direction of the relationship between age and hormones to be consistent across existing studies, although the mean hormone values fluctuate with different sample sizes. We would expect standard error estimates to decrease with additional patients, and for means to be more consistent across studies with the same inclusionary and exclusionary criteria.
Finally, a case-control design utilizing agematched participants would provide the most objective means of understanding normal vs abnormal hormone levels over the course of the female life cycle. Having established what we believe to be a credible, clinical guideline to normal values, based on comparison to similar studies, we will investigate and compare the androgen values in women with and without sexual dysfunction in future studies.
